GA-IDEMIA
10.2.2021 14:02:11 CET | Business Wire | Press release
Honeywell (NYSE: HON) , a global leader in connected buildings, and IDEMIA, the global leader in Augmented Identity, today announced a strategic alliance to create and cultivate an intelligent building ecosystem that provides a more seamless and enhanced experience for operators and occupants alike. The alliance will integrate Honeywell’s security and building management systems with IDEMIA’s biometric-based access control systems to create frictionless, safer and more efficient buildings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005454/en/
The Honeywell and IDEMIA alliance is intended to design solutions that will allow occupants to easily and securely have contactless engagement with a building – from vehicle recognition at the car park and automatic elevator calls to biometric-based access and personalized conference room settings. With a focus on security and data privacy, these next-generation solutions will provide occupants with a safer, more efficient and more enjoyable experience that will help building owners attract tenants.
“We recognize that our customers need to deliver business outcomes like managing complex security requirements and providing healthier, more productive environments,” said Manish Sharma, vice president, chief technology and chief product officer for Honeywell Building Technologies. “By working with IDEMIA we will create an intelligent building ecosystem that better addresses our customers’ key challenges and drives their desired outcomes. Whether it’s a commercial office building, a hospital or an airport, we have the ability to change the way people experience and interact with buildings for the better.”
“We look forward to expanding our long-standing relationship with Honeywell to bring greater value to our customers with more integrated solutions that make for a more seamless building experience,” said Matt Cole, CEO, Secure Enterprise Transactions Division, IDEMIA. “The ability for our technology to easily integrate with Honeywell safety and security systems will provide building owners and operators more insight and control into creating more efficient buildings, while putting the occupant experience first.”
IDEMIA’s field-proven AI-based products and solutions -- like MorphoWave TM , a contactless fingerprint device that scans four fingerprints in less than one second; VisionPass, the most advanced facial recognition terminal; or Augmented Vision, a biometric video analytics platform -- integrate with Honeywell security and building management systems. Honeywell’s systems include Pro-Watch Integrated Security Suite, MAXPRO Cloud and Enterprise Buildings Integrator.
Honeywell and IDEMIA will work together to deliver more powerful integrations through aligned product creation and joint product roadmaps. The integrated offerings will allow building operators to respond rapidly and effectively to alarms or incidents by providing an incident workflow package that allows Standard Operating Procedures (SOPs) to be configured, reducing compliance exceptions, security risks and response times.
IDEMIA products also support Honeywell’s Healthy Buildings solutions that help building owners improve building environments, operate more cleanly and safely and encourage sustained compliance with changing building standards, safety guidelines, government-issued regulations and a company's risk management policies. Honeywell's Healthy Buildings solutions provide a holistic view of a building's health based on key factors such as indoor air quality, occupant flow, personal protection equipment (PPE) analytics, contactless access, thermal screening, social distancing and sanitation efficacy.
To learn more about Honeywell and IDEMIA collaborations click here .
# # #
About IDEMIA
IDEMIA, the global leader in augmented identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for augmented identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide augmented identity for international clients from financial, telecom, identity, public security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter.
About Honeywell Building Technologies
Honeywell Building Technologies (HBT) is a global business with more than 18,000 employees. HBT creates products, software and technologies found in more than 10 million buildings worldwide. Commercial building owners and operators use our technologies to help create safe, energy efficient, sustainable and productive facilities. For more news and information on Honeywell Building Technologies, visit http://www.honeywell.com/newsroom .
Honeywell (www.honeywell.com ) is a Fortune 100 technology company that delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005454/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
